Modern Retina Newsletter

To view this email as a web page, click here.

Diabetic eye disease advances, but questions remain

With all the technological and medical advances for the treatment of diabetic eye diseases, retinal specialists still have an ongoing therapy issue because patients require continual and constant monitoring and maintenance.

Continue

Anti-VEGFs can improve DRSS in majority of patients

Using a specific anti-VEGF drug in patients with moderately severe to severe nonproliferative diabetic retinopathy can result in a ≥2-step improvement in diabetic retinopathy severity scores (DRSS) in almost 60% of those treated.

Find out

What retinal specialists should know about their pregnant patients

Advancing pregnancy induces obvious physical changes for women over time. However, numerous not-so-obvious physiologic, hormonal, and metabolic changes also occur during pregnancy of which ophthalmologists should make themselves aware.

What to know about this rare inherited retinal disease

How retinal surgeons are practicing in 2018

Brolucizumab: Next-generation of anti-VEGF therapy?

Risuteganib for the treatment of DME

Dinner program with expert presentations on Wet AMD and DME – Saturday, October 27, 2018 in Chicago, brought to you by Ophthalmology Times and Regeneron.

Save your seat now. »

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.